A1c Change from 5.5% to 5.6% Over Two Months on Risperidone: Not a Rapid Increase
An A1c increase from 5.5% to 5.6% over two months is not a rapid increase and falls well within normal laboratory variability and the expected metabolic effects of risperidone. This minimal change does not warrant immediate intervention or medication discontinuation.
Understanding the Context
Normal A1c Variability
Laboratory measurements of A1c inherently contain variability. The coefficient of variation for standardized A1c assays is approximately 4% 1, meaning that repeat measurements on the same sample can vary by this amount without representing true physiological change. A 0.1% absolute change (from 5.5% to 5.6%) is clinically insignificant and likely represents normal assay variability rather than true glycemic deterioration 2.
A1c Kinetics and Timeframe
Approximately 50% of A1c reflects glycemia from the most recent month, 25% from 30-60 days prior, and 25% from 60-120 days before measurement 1. At two months post-risperidone initiation, you're capturing a transitional period where the A1c hasn't fully equilibrated to reflect the medication's metabolic effects. The full impact of antipsychotic-induced metabolic changes typically requires longer observation periods.
Risperidone's Metabolic Profile
Expected Glycemic Changes
The FDA label for risperidone documents mean glucose increases of +0.8 mg/dL (1-8 mg/day dose) and +2.8 mg/dL at 24 weeks in clinical trials 3. These modest changes in serum glucose would translate to minimal A1c elevations over time. Research shows that while antipsychotics increase diabetes risk, mean A1c levels in patients with first-episode schizophrenia remained stable at 37 mmol/mol (approximately 5.5%) during the first 2 years of treatment 4.
What Constitutes Concerning Change
In bipolar patients on antipsychotics, a study found slight (non-significant) A1c increases over time, but these were measured over longer periods 5. A concerning rapid increase would be movement from normal range (<5.7%) into prediabetes range (5.7-6.4%) or diabetes range (≥6.5%) within weeks to months, not a 0.1% fluctuation within the normal range.
Clinical Approach
Monitoring Strategy
- Continue risperidone without modification - both values (5.5% and 5.6%) are in the normal range (<5.7%)
- Recheck A1c at 3-6 months to assess for sustained trends 3
- Monitor fasting glucose periodically as it may detect changes earlier than A1c 1
- Watch for hyperglycemia symptoms (polydipsia, polyuria, polyphagia, weakness) 3
When to Intervene
Intervention would be warranted if:
- A1c crosses into prediabetes range (≥5.7%) on repeat testing
- A1c increases by ≥0.5% over 3-6 months
- Fasting glucose becomes elevated (≥100 mg/dL)
- Patient develops symptoms of hyperglycemia
Important Caveats
Hemoglobin variants can cause spurious A1c results 1. If you see discordant results between A1c and glucose measurements, consider checking for hemoglobin variants, particularly in patients of African, Mediterranean, or Southeast Asian descent. The case literature documents rare instances of dramatically discordant A1c values due to assay interference 6.
Risk Stratification
Patients at higher risk for antipsychotic-induced metabolic complications include those with:
- Obesity or family history of diabetes 3
- Baseline prediabetes (A1c 5.7-6.4%)
- Concurrent use of other metabolically active medications
For this patient with both values in the normal range, the current trajectory does not suggest accelerated metabolic dysfunction. The 8-10% incidence of diabetes in patients with schizophrenia on antipsychotics develops over years, not months 4.